#USA #San Diego #Alzheimer's Disease #CircPATH #Circular RNAs

Circular Genomics Introduces CircPATH™

On July 2, 2026, Circular Genomics made a significant announcement with the unveiling of its CircPATH™ platform, which is poised to transform Alzheimer’s disease (AD) detection. Following a groundbreaking study published in Nature Medicine, this innovative approach utilizes blood-based circular RNA (circRNA) biomarkers that surpass traditional diagnostic methods. This study, spearheaded by Dr. Carlos Cruchaga at Washington University in St. Louis, is considered a watershed moment in the realm of neurodegenerative disease research.

The CircPATH™ technology stands at the forefront of innovations that connect novel RNA biology to actionable clinical tools. The findings from the study illustrate that the identified circRNA biomarkers not only detect the presence of Alzheimer’s disease but also track its progression with exceptional accuracy. These biomarkers can foresee the development of symptoms even before they manifest, thus facilitating preclinical risk stratification that could revolutionize patient care.

The results of the study are impressive—in large cohorts of nearly 2,400 participants, circRNA biomarkers showed an accuracy rate with an area under the curve (AUC) of 0.945 for confirming cases of Alzheimer’s in symptomatic patients. Even more astounding is the AUC of 0.870 for predicting Alzheimer’s development in individuals without current symptoms. This predictive power represents a staggering 61% enhancement in identifying at-risk individuals compared to existing gold standard measures, such as pTau217. By integrating the circRNA measurements with pTau217, the diagnostic accuracy approaches near perfection with an AUC of 0.967.

These circular RNAs are brain-derived and possess the unique ability to cross the blood-brain barrier, providing insights into central nervous system conditions via a simple blood test. This method captures the vast complexity of Alzheimer’s biology—including amyloid and tau pathologies—thus enabling tailored approaches to patient care.

Dr. Cruchaga emphasized the revolutionary potential of these findings, highlighting that circRNAs change long before symptoms appear, thus heralding a new era in precision neurology. The implications for improved clinical care are immense, allowing clinicians to intervene earlier and customize treatments based on the specific biological pathways highlighted by the circRNA signatures.

In addition to diagnosis, circRNA biomarkers streamline clinical trials. By specifically identifying individuals who are most likely to progress, they reduce the time and resources needed for research studies. Moreover, the utilization of circRNA in stratification strategies can isolate patients who will derive the most benefit from specific treatments, thereby expediting the path to market approval for innovative therapies.

This proprietary CircPATH™ engine not only recognizes but also evaluates the performance of these circRNAs in larger, diverse populations. This thorough validation process ensures the biomarkers maintain their effectiveness across different cohorts, thus solidifying their role in advancing the diagnostics landscape.

Despite the current challenges in Alzheimer’s disease management, Circular Genomics is optimistic about the future. They continuously develop additional circRNA-based diagnostics targeting not only Alzheimer’s but also other neurodegenerative disorders such as Parkinson’s disease. By incorporating CircPATH™ markers into drug development programs and clinical practice, Circular Genomics aims to enhance both early detection and patient outcomes significantly.

With their headquarters in San Diego, California, Circular Genomics stands at the forefront of a medical revolution, leveraging advanced RNA technology to improve the lives of millions impacted by neurodegenerative diseases. Their endeavors signal a promising future in the realm of Alzheimer's diagnosis, treatment, and overall patient care.